KRTL Holding Group Acquires Neurogen Brain Balancing, LLC

KRTL Biotech (KRTL Holding) Acquires Majority Interest in Sigma Corp (Bolivia)

September 2, 2025

Pharmaceuticals

KRTL Biotech, a wholly owned subsidiary of KRTL Holding Group, Inc., completed a merger-by-exchange to acquire 99% of Industria Químico Farmacéutica Sigma Corp. S.R.L. (SIGMA), a Bolivian pharmaceutical manufacturer. The Wilstermann Family received 490,000,000 KRTL Biotech common shares (49% of KRTL Biotech) and Patricia Wilstermann received a preferred share and a permanent board seat; SIGMA will be consolidated into KRTL Biotech's financials under U.S. GAAP.

Engrail Therapeutics Acquires NeuroCycle Therapeutics

February 2, 2021

Biotechnology

Engrail Therapeutics has acquired NeuroCycle Therapeutics, a small neuroscience company focused on sub-type selective GABA-A modulation. The acquisition expands Engrail's GABA-A portfolio and provides a platform to advance multiple assets toward clinical trials and further pipeline development.

Kandu Health and Neurolutions Merge to Form Kandu, Inc.; $30M Financing Co‑Led by Ally Bridge Group and AMED Ventures

April 8, 2025

Healthcare Services

Kandu Health and Neurolutions have merged to form Kandu, Inc., combining Neurolutions' FDA‑cleared IpsiHand brain‑computer interface device with Kandu Health's AI‑supported telehealth stroke‑recovery services. The newly formed company closed the first tranche of a $30 million financing co‑led by Ally Bridge Group and AMED Ventures to support commercialization and continued product and service integration.

CBC Group and Mubadala Acquire UCB's Mature China Neurology & Allergy Portfolio to Create NeuroGen Pharma

November 29, 2024

Pharmaceuticals

CBC Group, in partnership with Mubadala Investment Company, has completed the US$680 million acquisition of UCB’s mature neurology and allergy product portfolio in China, including brands such as Keppra, Vimpat, Neupro, Zyrtec and Xyzal and a manufacturing site in Zhuhai. The assets have been combined into a new company named NeuroGen Pharma as an anchor platform to build an integrated CNS biopharma business in China and expand capability in neurology and allergy treatments.

KNR Therapy (backed by Shields Capital) Merges with The Autism Learning Center

January 31, 2022

Healthcare Services

KNR Therapy, supported by Shields Capital, has merged with The Autism Learning Center (ALC), a founder-led ABA therapy provider based in Columbus, Georgia. The combination expands KNR's geographic footprint across Georgia and Alabama and brings ALC's clinic- and school-based ABA services and team into the KNR platform.

Lantheus Holdings Acquires Cerveau Technologies

February 6, 2023

Pharmaceuticals

Lantheus Holdings, Inc. acquired Knoxville-based Cerveau Technologies, Inc., gaining MK-6240, a clinical-stage F-18 PET imaging agent that targets Tau tangles in Alzheimer's disease. The stock purchase includes upfront and potential milestone payments plus royalty obligations and will expand Lantheus' radiopharmaceutical diagnostic imaging pipeline and research collaborations.